Clover Health Investments, Corp. (CLOV)
NASDAQ: CLOV · Real-Time Price · USD
2.210
-0.050 (-2.21%)
At close: Aug 7, 2025, 4:00 PM
2.220
+0.010 (0.45%)
After-hours: Aug 7, 2025, 7:58 PM EDT
Elevation Oncology Stock Forecast
Stock Price Forecast
The 3 analysts that cover Elevation Oncology stock have a consensus rating of "Strong Buy" and an average price target of $4.37, which forecasts a 97.74% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $6.00.
Price Target: $4.37 (+97.74%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Elevation Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.5 → $4.1 | Strong Buy | Maintains | $4.5 → $4.1 | +85.52% | Aug 7, 2025 |
| UBS | UBS | Hold Maintains $4.5 → $3 | Hold | Maintains | $4.5 → $3 | +35.75% | Aug 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.2 → $4.5 | Strong Buy | Maintains | $4.2 → $4.5 | +103.62% | Mar 3, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +171.49% | Dec 17, 2024 |
| UBS | UBS | Hold Initiates $4 | Hold | Initiates | $4 | +81.00% | Oct 7, 2024 |
Financial Forecast
Revenue This Year
1.90B
from 1.37B
Increased by 38.62%
Revenue Next Year
2.32B
from 1.90B
Increased by 22.21%
EPS This Year
-0.13
from -0.09
EPS Next Year
-0.13
from -0.13
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.0B | 2.5B | 2.7B | ||
| Avg | 1.9B | 2.3B | 2.5B | ||
| Low | 1.8B | 2.1B | 2.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 44.6% | 30.1% | 17.1% | ||
| Avg | 38.6% | 22.2% | 7.8% | ||
| Low | 31.3% | 9.6% | -5.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.11 | -0.11 | 0.04 | ||
| Avg | -0.13 | -0.13 | -0.01 | ||
| Low | -0.16 | -0.15 | -0.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.